This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Market Welcomes Novartis Reshuffle

NEW YORK ( TheStreet) -- The market is responding positively Tuesday to a series of management changes at Novartis (NVS - Get Report), including Daniel Vasella's step-down as CEO.

Joe Jimenez, head of the drugs division, will replace Vasella, 57, as CEO on Feb. 1.

The move comes amid stiff competition in the drug market, where patent expirations are a mounting problem.

Many at Novartis believed that COO Joerg Reinhardt was to succeed Jimenez, but he is leaving the company, instead. Reinhardt's position has been eliminated.

Meanwhile, Jon Symonds, plucked from Goldman Sachs last year, will serve as the new CFO. Symonds is replacing Raymund Breu on Feb. 1. Breu is retiring at the end of March.

David Epstein, head of Novartis's oncology business, will replace Jimenez as head of the pharmaceuticals division.

The market seems to welcome the changes.

Novartis stock has risen 1.3% at the start of the trading session to $54.10.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
RHHBY $31.69 0.00%
GSK $40.76 0.00%
MRK $49.38 0.00%
NVS $74.33 0.00%
AAPL $94.02 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs